Mipsagargin

Drug Profile

Mipsagargin

Alternative Names: G-202; Thapsigargin prodrug

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University
  • Developer Inspyr Therapeutics; National Cancer Institute (USA); University of Texas Health Science Center at Houston
  • Class Antineoplastics; Drug conjugates; Lactones; Peptides; Sesquiterpenes
  • Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Hepatocellular carcinoma; Prostate cancer; Renal cell carcinoma
  • Preclinical Cancer; Gastric cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Aug 2017 Preclinical trials in Cancer (Combination therapy) in USA (unspecified route) (Inspyr Therapeutics pipeline, August 2017)
  • 04 Aug 2017 Preclinical trials in Cancer in USA (unspecified route) (Inspyr Therapeutics pipeline, August 2017)
  • 04 Aug 2017 Inspyr Therapeutics plans a clinical trial for Hepatocellular carcinoma(Monotherapy) in second half of 2017 (Inspyr Therapeutics pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top